Methylation testing for the detection of recurrent cervical intraepithelial neoplasia.
DNA methylation
cervical cancer
high-grade CIN
posttreatment surveillance
recurrent CIN
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2023
15 12 2023
Historique:
received:
13
06
2023
accepted:
19
07
2023
medline:
23
10
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Women treated for CIN2/3 remain at increased risk of recurrent CIN and cervical cancer, and therefore posttreatment surveillance is recommended. This post hoc analysis evaluates the potential of methylation markers ASCL1/LHX8 and FAM19A4/miR124-2 for posttreatment detection of recurrent CIN2/3. Cervical scrapes taken at 6 and 12 months posttreatment of 364 women treated for CIN2/3 were tested for methylation of ASCL1/LHX8 and FAM19A4/miR124-2 using quantitative multiplex methylation-specific PCR. Performance of the methylation tests were calculated and compared with the performance of HPV and/or cytology. Methylation levels of recurrent CIN were compared between women with a persistent HPV infection, and women with an incident HPV infection or without HPV infection. Recurrent CIN2/3 was detected in 42 women (11.5%), including 28 women with CIN2 and 14 with CIN3. ASCL1/LHX8 tested positive in 13/14 (92.9%) of recurrent CIN3 and 13/27 (48.1%) of recurrent CIN2. FAM19A4/miR124-2 tested positive in 14/14 (100%) of recurrent CIN3 and 10/27 (37.0%) of recurrent CIN2. Combined HPV and/or methylation testing showed similar positivity rates as HPV and/or cytology. The CIN2/3 risk at 12 months posttreatment was 30.8% after a positive ASCL1/LHX8 result at 6 months posttreatment. Methylation levels of CIN2/3 in women with a persistent HPV infection were significantly higher compared with women with an incident or no HPV infection. In conclusion, posttreatment monitoring by methylation analysis of ASCL1/LHX8 and FAM19A4/miR124-2 showed a good performance for the detection of recurrent CIN. DNA methylation testing can help to identify women with recurrent CIN that require re-treatment.
Banques de données
NTR
['NTR1964']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2011-2018Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118(8):2048-2055. doi:10.1002/ijc.21604
Rebolj M, Helmerhorst T, Habbema D, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ. 2012;345:e6855. doi:10.1136/bmj.e6855
Strander B, Andersson-Ellström A, Milsom I, Sparén P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335(7629):1077. doi:10.1136/bmj.39363.471806.BE
Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ. 2014;348:f7361. doi:10.1136/bmj.f7361
Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12(5):441-450. doi:10.1016/s1470-2045(11)70078-x
Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88-F99. doi:10.1016/j.vaccine.2012.06.095
Clarke MA, Unger ER, Zuna R, et al. A systematic review of tests for Postcolposcopy and Posttreatment surveillance. J Lower Genit Tract Dis. 2020;24(2):148-156. doi:10.1097/lgt.0000000000000526
Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol. 2016;76(suppl 1):S56-s61. doi:10.1016/j.jcv.2015.10.008
Tainio K, Athanasiou A, Tikkinen KAO, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499. doi:10.1136/bmj.k499
Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25. doi:10.1097/AOG.0b013e31818f5008
Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633. doi:10.1136/bmj.i3633
Loopik DL, van Drongelen J, Bekkers RLM, et al. Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: a Dutch population-based cohort study with 45,259 pregnancy outcomes. PLoS Med. 2021;18(6):e1003665. doi:10.1371/journal.pmed.1003665
Wiik J, Nilsson S, Kärrberg C, Strander B, Jacobsson B, Sengpiel V. Associations of treated and untreated human papillomavirus infection with preterm delivery and neonatal mortality: a Swedish population-based study. PLoS Med. 2021;18(5):e1003641. doi:10.1371/journal.pmed.1003641
de Strooper LM, Meijer CJ, Berkhof J, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res. 2014;7(12):1251-1257. doi:10.1158/1940-6207.capr-14-0237
Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2013;133(6):1293-1299. doi:10.1002/ijc.28138
Kremer WW, Dick S, Heideman DAM, et al. Clinical regression of high-grade cervical intraepithelial neoplasia is associated with absence of FAM19A4/miR124-2 DNA methylation (CONCERVE study). J Clin Oncol. 2022;40(26):3037-3046. doi:10.1200/jco.21.02433
Uijterwaal MH, Van Zummeren M, Kocken M, et al. Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN. Gynecol Oncol. 2016;143(1):135-142. doi:10.1016/j.ygyno.2016.07.089
Dick S, Verhoef L, De Strooper LM, et al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics. 2020;12(18):1569-1578. doi:10.2217/epi-2019-0331
Bonde J, Floore A, Ejegod D, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int J Cancer. 2021;148(2):396-405. doi:10.1002/ijc.33320
Verhoef L, Bleeker MCG, Polman N, et al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort. Int J Cancer. 2022;150(3):440-449. doi:10.1002/ijc.33820
Van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40(3):779-787.
Bulk S, Van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol. 2004;57(4):388-393.
Kennisinstituut van de Federatie van Medisch Specialisten. Richtllijn CIN, AIS en VAIN. https://richtlijnendatabase.nl/richtlijn/cin_ais_en_vain/follow_up/na_behandelde_cin2_3.html
Verlaat W, Snoek BC, Heideman DAM, et al. Identification and validation of a 3-gene methylation classifier for HPV-based cervical screening on self-samples. Clin Cancer Res. 2018;24(14):3456-3464. doi:10.1158/1078-0432.Ccr-17-3615
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108.
De Strooper LMA, Berkhof J, Steenbergen RDM, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow-up. Int J Cancer. 2018;143(6):1541-1548. doi:10.1002/ijc.31539
Bottari F, Iacobone AD, Passerini R, et al. Human papillomavirus genotyping compared with a qualitative high-risk human papillomavirus test after treatment of high-grade cervical intraepithelial neoplasia: a systematic review. Obstet Gynecol. 2019;134(3):452-462. doi:10.1097/aog.0000000000003409
Iacobone AD, Radice D, Sandri MT, et al. Human papillomavirus same genotype persistence and risk of cervical intraepithelial Neoplasia2+ recurrence. Cancers. 2021;13(15). doi:10.3390/cancers13153664
Ouh YT, Cho HW, Kim SM, et al. Risk factors for type-specific persistence of high-risk human papillomavirus and residual/recurrent cervical intraepithelial neoplasia after surgical treatment. Obstet Gynecol Sci. 2020;63(5):631-642. doi:10.5468/ogs.20049
Söderlund-Strand A, Kjellberg L, Dillner J. Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. J Med Virol. 2014;86(4):634-641. doi:10.1002/jmv.23806
Mariani L, Sandri MT, Preti M, et al. HPV-testing in follow-up of patients treated for CIN2+ lesions. J Cancer. 2016;7(1):107-114. doi:10.7150/jca.13503
Venturoli S, Ambretti S, Cricca M, et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol. 2008;80(8):1434-1440. doi:10.1002/jmv.21198